Asia Pacific Acute Pancreatitis Market Forecast to 2030 - Regional Analysis

List of Tables

The Asia Pacific acute pancreatitis market was valued at US$ 607.35 million in 2022 and is expected to reach US$ 1,076.06 million by 2030; it is estimated to grow at a CAGR of 7.4% from 2022 to 2030.

Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis Fuels the Asia Pacific Acute Pancreatitis Market

Extensive research studies are being conducted globally to investigate the etiology, progress, and treatment of acute pancreatitis. The National Pancreas Foundation (NPF) provides multiple research grants worth ~US$ 50,000 per project. To date, the NPF has provided more than US$ 5 million for 133 ground-breaking research projects. A grant is awarded for a period of a year to diagnose and/or treat pancreatitis, pancreatic cancer, or pediatric pancreatitis.

Further, several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. Thus, R&D activities and awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to be highly fruitful for companies in the Asia Pacific acute pancreatitis market.

Asia Pacific Acute Pancreatitis Market Overview

The Asia Pacific acute pancreatitis market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including rising cases of pancreatitis, researchers to develop a treatment for pancreatitis, and government efforts to raise awareness among the population. In addition, alcohol-related pancreatitis cases also fuel the growth of the market in the region. The prevalence of pancreatitis has shown an upward trend in recent years in China. According to a study titled "Burden of Pancreatitis and associated risk factors in China, 1990 to 2019," published in 2022, alcohol consumption has become an important cause in the disease burden of pancreatitis in recent years in the country. In China, cases of alcoholic pancreatitis are significantly higher compared to 10 years ago. In the country, the number of pancreatitis cases was 380,018 in 1990 and 493,765 in 2019. From 1990 to 2019, the total number of deaths due to pancreatitis also increased, accounting for 8,976 in 1990 and 10,664 in 2019. In 2019, the number of deaths due to alcohol-related pancreatitis was 3,327.29 in the country, accounting for 31.20% of the total deaths due to pancreatitis.

Asia Pacific Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific Acute Pancreatitis Market Segmentation

The Asia Pacific acute pancreatitis market is segmented offerings, causes, end user, and country.

Based on offerings, the Asia Pacific acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.

Based on method, the Asia Pacific acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.

Based on end user, the Asia Pacific acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Asia Pacific acute pancreatitis market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific acute pancreatitis market in 2022.

Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the Asia Pacific acute pancreatitis market.

Product Code: BMIRE00029216

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Asia Pacific Acute Pancreatitis Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Acute Pancreatitis Market Landscape

4.1 Overview

5. Asia Pacific Acute Pancreatitis Market - Key Industry Dynamics

5.1 Key Market Drivers
- 5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
- 5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
5.2 Key Market Restraints
- 5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
5.3 Key Market Opportunities
- 5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
5.4 Future Trends
- 5.4.1 Advancements in Specific Acute Pancreatitis Treatments
5.5 Impact Analysis:

6. Acute Pancreatitis Market - Asia Pacific Market Analysis

6.1 Asia Pacific Acute Pancreatitis Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings

7.1 Overview
7.2 Asia Pacific Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
7.3 Medications
- 7.3.1 Overview
- 7.3.2 Medications: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.1 Asia Pacific Acute Pancreatitis Market, by Medications, 2020-2030 (US$ Million)
7.4 Diagnosis
- 7.4.1 Overview
- 7.4.2 Diagnosis: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Asia Pacific Acute Pancreatitis Market, by Diagnosis, 2020-2030 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes

8.1 Overview
8.2 Asia Pacific Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
8.3 Gallstones
- 8.3.1 Overview
- 8.3.2 Gallstones: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Alcoholism
- 8.4.1 Overview
- 8.4.2 Alcoholism: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Genetic Disorders
- 8.5.1 Overview
- 8.5.2 Genetic Disorders: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Infections
- 8.6.1 Overview
- 8.6.2 Infections: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Asia Pacific Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
- 9.4.1 Overview
- 9.4.2 Diagnostic Laboratories: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Ambulatory Surgical Centers
- 9.5.1 Overview
- 9.5.2 Ambulatory Surgical Centers: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Asia Pacific Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Acute Pancreatitis Market - Country Analysis

10.1 Overview

11. Asia Pacific Acute Pancreatitis Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Asia Pacific Acute Pancreatitis Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 GE HealthCare Technologies Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Samsung Healthcare
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Koninklijke Philips NV
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Baxter International Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Dynavax Technologies Corp
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Fresenius Kabi AG
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Medtronic Plc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Boston Scientific Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms